Arcus Biosciences, Inc. (RCUS) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
RCUS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RCUS Revenue Analysis (2016–2025)
As of February 28, 2026, Arcus Biosciences, Inc. (RCUS) generated trailing twelve-month (TTM) revenue of $247.0 million, reflecting exceptional growth of +26.9% year-over-year. The most recent quarter (Q4 2025) recorded $33.0 million in revenue, up 26.9% sequentially.
Looking at the longer-term picture, RCUS's 5-year compound annual growth rate (CAGR) stands at +25.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $383.0 million in 2021.
Revenue diversification analysis shows RCUS's business is primarily driven by License And Development Services (87%), Development Services (7%), and R&D Services (3%). With over half of revenue concentrated in License And Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY), RCUS has underperformed the peer group in terms of revenue growth. Compare RCUS vs INCY →
Peer Comparison
Compare RCUS's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RCUSCurrent | $247M | +26.9% | +25.9% | -156.3% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $247.0M | -4.3% | $0 | - | $-386,000,000 | -156.3% |
| 2024 | $258.0M | +120.5% | $258.0M | 100.0% | $-330,000,000 | -127.9% |
| 2023 | $117.0M | +4.5% | $117.0M | 100.0% | $-340,000,000 | -290.6% |
| 2022 | $112.0M | -70.8% | $112.0M | 100.0% | $-280,000,000 | -250.0% |
| 2021 | $383.0M | +391.0% | $383.0M | 100.0% | $54.0M | 14.1% |
| 2020 | $78.0M | +420.0% | $78.0M | 100.0% | $-124,000,000 | -159.0% |
| 2019 | $15.0M | +79.6% | $15.0M | 100.0% | $-88,709,000 | -591.4% |
| 2018 | $8.4M | +491.2% | $8.4M | 100.0% | $-54,859,000 | -656.8% |
| 2017 | $1.4M | - | $1.4M | 100.0% | $-53,441,000 | -3782.1% |
| 2016 | $0 | - | $-1,314,000 | - | $-18,182,000 | - |
See RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RCUS vs AGIO
See how RCUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RCUS's revenue growth accelerating or slowing?
RCUS revenue is accelerating at +26.9% year-over-year, exceeding the 5-year CAGR of +25.9%. TTM revenue reached $247M. Growth momentum has increased versus prior periods.
What is RCUS's long-term revenue growth rate?
Arcus Biosciences, Inc.'s 5-year revenue CAGR of +25.9% reflects the sustained expansion pattern. Current YoY growth of +26.9% is above this long-term average.
How is RCUS's revenue distributed by segment?
RCUS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.